Search Results

You searched for : boehringeringelheim

	Boehringer Ingelheim's Investigational Treatment for Schizophrenia receives FDA Breakthrough Therapy Designation The company also announced the planned initiation of the innovative CONNEX Phase III clinical trial program assessing the safety and efficacy of BI 425809 ... May 27
	New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1 New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1... Nov 07
	Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets Empagliflozin and Linagliptin tablets, have an estimated market size of US$ 244 million for twelve months ending June 2020... Aug 27
	Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio Boehringer Ingelheim Acquires Northern Biologicsâ€™ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio ... May 16
	Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease European Medicines Agency (EMA) has adopted a positive opinion recommending granting marketing authorisation for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease (... Mar 03
	Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies ... Sep 21
6 Matching result(s) found!

-Advertisements-

Trending Now
	Stay Cool This Summer: Government of India’s Guidelines for Heat ProtectionJune 01, 2024
	India's Commitment to Women's, Children's, and Adolescent's Health Highlighted at World Health AssemblyJune 01, 2024
	Sleep Your Way to a More Connected Life: The Role of Sleep in Combating LonelinessJune 01, 2024
	Moscow Outpatient Departments to Implement AI X-ray InterpretationMay 31, 2024
	FLO launched Digital Ready Reckoner - of MSME schemes.May 31, 2024
	Candy flavoured traps to hook the next generationMay 31, 2024
	Software Engineering Research Centre (SERC) at IIIT H to host 21st Edition of IEEE International Conference on Software Architecture (ICSA) 2024May 31, 2024
	Federal Bank and Tata AIA Life Insurance Announce Strategic Bancassurance PartnershipMay 31, 2024
	Why Whole Spices are Better than Powdered: New ICMR GuidelinesMay 31, 2024
	Raising Awareness on Menstrual Health: NCW and SheWings Initiative on Menstrual Hygiene DayMay 31, 2024
	Innovative RNA Drugs Offer Hope for Patients with High CholesterolMay 31, 2024
	Advani Hotels & Resorts (India) Limited (Caravela Beach Resort, Goa)May 30, 2024
	FLO Hyderabad launches ‘Centre of Excellence for Training Women Vegetable Farming’May 30, 2024
	Should Doctors Be Exempt from the Consumer Protection Act? A Complex DebateMay 30, 2024
	Tamil Nadu Doctors Save 14-Year-Old Girl by Removing Needle from Lung with BronchoscopyMay 30, 2024
	The Lifesaving Journey of a Florist: Rare 'Bombay' Blood Group Donation Saves Life May 30, 2024
	The Impact of Heat on Eye Health: Preventing Eye Strokes During High TemperaturesMay 30, 2024
	Patients with super morbid obesity can find life-changing benefits beyond weight reduction through bariatric surgeryMay 29, 2024
	AI software could revolutionise voice box cancer treatmentMay 29, 2024
	Why You’re Waking Up to Pee: The Link Between Enlarged Prostate and NocturiaMay 29, 2024

Search Results

Boehringer Ingelheim's Investigational Treatment for Schizophrenia receives FDA Breakthrough Therapy Designation

New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1

Alembic Pharma receives USFDA tentative approval for Empagliflozin and Linagliptin tablets

Boehringer Ingelheim Acquires Northern Biologics, Expanding Immuno-oncology Portfolio

Boehringer Ingelheim receives positive CHMP opinion for nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Trending Now